Onconetix, Inc. (Nasdaq: ONCO) has provided a bridge financing facility of up to $5,000,000 to Realbotix LLC, the target of its pending acquisition, with an initial advance of $2,500,000, according to a press release dated Sept. 14, 2026.

The facility is non-interest bearing prior to the closing of the Share Exchange Agreement between the two companies. Upon closing, the facility and all obligations will be automatically cancelled and discharged in full. The cash required at closing will also be reduced by the total principal advanced under the facility plus an additional $500,000.

If the Share Exchange Agreement is terminated, interest will accrue at 12% per annum from the date of termination.

Onconetix originally announced the Share Exchange Agreement on Feb. 12, 2026, under which it agreed to acquire 100% of the issued and outstanding equity interests of Realbotix LLC in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which remains subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.

Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; OTC: XBOTF) and develops AI-powered humanoid robots manufactured in the United States.

Onconetix is a Cincinnati, Ohio-based biotechnology company focused on oncology, and owns Proclarix, a prostate cancer diagnostic test approved for sale in the European Union.